中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

老年人非酒精性脂肪性肝病与骨质疏松的关联分析

薛倩 贾春玲 王晶桐

引用本文:
Citation:

老年人非酒精性脂肪性肝病与骨质疏松的关联分析

DOI: 10.12449/JCH240813
基金项目: 

国家重大疾病多学科合作诊疗能力建设项目 (2020);

北京大学医学部大健康国际研究院项目 (JKCJ202102)

伦理学声明:本研究于2021年2月19日经北京大学人民医院伦理审查委员会批准,批号:2021PHB044-001,所有患者知情同意并签署知情同意书。
利益冲突声明:本文不存在任何利益冲突。
作者贡献声明:薛倩、贾春玲负责文章的构思、研究的设计与可行性分析;薛倩负责资料收集、整理并撰写论文;王晶桐负责文章的质量控制及审校。
详细信息
    通信作者:

    王晶桐, wangjingtong11@163.com (ORCID: 0000-0002-8203-1323)

Association between nonalcoholic fatty liver disease and osteoporosis in elderly patients

Research funding: 

National Project of Multidisciplinary Diagnosis and Treatment of Major Diseases (2020);

International Institute of Population Health, Peking University Health Science Center (JKCJ202102)

More Information
  • 摘要:   目的  分析老年人非酒精性脂肪性肝病(NAFLD)与骨质疏松的关系及影响因素。  方法  选取2016年6月—2023年4月于北京大学人民医院老年科住院的年龄≥60岁的824例患者,其中骨质疏松组398例,非骨质疏松组426例。收集研究对象的一般资料、血生化指标,肝脏B超检查及双光能X线骨密度结果等。符合正态分布的计量资料2组间比较采用成组t检验,非正态分布的计量资料2组间比较采用Mann-Whitney U检验,分类变量采用χ2检验进行分析;采用二元Logistic回归分析骨质疏松的独立影响因素。  结果  与非骨质疏松组相比,骨质疏松组年龄较大,女性更多见,糖尿病占比较高,身体质量指数(BMI)较低,差异均有统计学意义(P值均<0.05)。骨质疏松组患者NAFLD占比高于非骨质疏松组(36.2% vs 24.6%,χ2=12.878,P<0.001)。骨质疏松组患者血红蛋白、尿酸、Alb水平低于非骨质疏松组,总胆固醇、低密度脂蛋白胆固醇(LDL-C)、骨特异性碱性磷酸酶、抗酒石酸酸性磷酸酶水平高于非骨质疏松组,差异均有统计学意义(P值均<0.05)。二元Logistic回归分析结果显示,高龄(OR=1.040,95%CI:1.015~1.066,P=0.002)、女性(OR=4.089,95%CI:2.607~6.411,P<0.001)、NAFLD(OR=1.697,95%CI:1.076~2.678,P=0.023)、糖尿病(OR=1.509,95%CI:1.008~2.260,P=0.046)、LDL-C(OR=1.431,95%CI:1.010~2.029,P=0.044)是老年患者骨质疏松的独立危险因素。考虑糖尿病对研究结果的影响,进一步对非糖尿病老年患者进行亚组分析,结果显示NAFLD仍是老年非糖尿病患者骨质疏松的独立危险因素(OR=1.573,95%CI:1.015~2.439,P=0.043)。  结论  NAFLD、高龄、女性是影响老年患者骨质疏松的独立危险因素。

     

  • 表  1  老年患者骨质疏松组与非骨质疏松组一般资料

    Table  1.   Comparison of general information between osteoporosis group and non-osteoporosis group in the elderly

    指标 骨质疏松组(n=398) 非骨质疏松组(n=426) 统计值 P
    女性[例(%)] 246(61.8) 123(28.9) χ2=90.265 <0.001
    年龄(岁) 78.08±8.51 76.09±9.25 t=-3.211 0.001
    BMI(kg/m2 23.15±5.00 24.48±4.75 t=3.902 <0.001
    高血压病史[例(%)] 253(63.6) 282(66.2) χ2=0.625 0.429
    糖尿病病史[例(%)] 193(48.5) 137(32.2) χ2=10.150 0.001
    冠心病病史[例(%)] 116(29.1) 131(30.8) χ2=0.253 0.615
    颈动脉粥样硬化[例(%)] 327(82.2) 352(82.6) χ2=0.036 0.850
    NAFLD[例(%)] 144(36.2) 105(24.6) χ2=12.878 <0.001
    下载: 导出CSV

    表  2  老年患者骨质疏松组与非骨质疏松组生化及代谢指标

    Table  2.   Comparison of biochemical and metabolic indicators between osteoporosis group and non-osteoporosis group in the elderly

    指标 骨质疏松组(n=398) 非骨质疏松组(n=426) 统计值 P
    Hb(g/L) 125.64±17.30 130.91±16.16 t=4.480 <0.001
    FPG(mmol/L) 5.64±1.83 5.74±1.94 t=0.785 0.433
    HbA1c(%) 6.62±2.99 6.22±1.54 t=1.789 0.074
    ALT(U/L) 14(10~20) 16(13~22) Z=-1.955 0.051
    AST(U/L) 19(16~23) 20(16~24) Z=-0.261 0.794
    TC(mmol/L) 4.43±1.09 4.22±1.48 t=-2.300 0.022
    TG(mmol/L) 1.25(0.93~1.69) 1.24(0.94~1.75) Z=-0.069 0.945
    LDL-C(mmol/L) 2.69±0.92 2.53±0.82 t=-2.550 0.011
    Alb(g/L) 38.11±6.42 39.10±7.34 t=2.078 0.038
    UA(μmol/L) 325.75±94.68 354.79±91.15 t=4.478 <0.001
    TSH(uIU/mL) 1.80(1.19~2.90) 1.85(1.17~2.77) Z=-0.074 0.941
    FINS(μIU/mL) 7.66(4.72~11.77) 8.28(4.88~12.12) Z=-0.640 0.522
    HOMA-IR 1.09(1.92~3.14) 2.14(1.26~3.34) Z=-1.718 0.086
    25(OH)D(ng/mL) 30.85(23.11~44.91) 35.00(23.50~50.64) Z=-1.515 0.130
    BSAP(ng/mL) 10.72±5.70 8.41±3.37 t=-6.204 <0.001
    TRAP(U/L) 4.13±1.95 3.59±1.16 t=-4.228 <0.001
    下载: 导出CSV

    表  3  老年患者骨质疏松影响因素的Logistic回归分析结果

    Table  3.   The results of Logistic regression analysis on the influencing factors of osteoporosis in elderly patients

    指标 回归系数 标准误 OR(95%CI P
    年龄 0.040 0.013 1.040(1.015~1.066) 0.002
    性别(女) 1.408 0.230 4.089(2.607~6.411) <0.001
    NAFLD 0.529 0.233 1.697(1.076~2.678) 0.023
    糖尿病 0.412 0.206 1.509(1.008~2.260) 0.046
    LDL-C 0.359 0.178 1.431(1.010~2.029) 0.044
    Alb -0.028 0.016 0.973(0.943~1.003) 0.074
    BMI -0.014 0.021 0.986(0.947~1.027) 0.504
    TC -0.079 0.103 0.924(0.755~1.130) 0.442
    UA -0.001 0.001 0.999(0.997~1.001) 0.460
    Hb 0.000 0.008 1.000(0.985~1.016) 0.975
    HOMA-IR 0.023 0.021 1.023(0.982~1.066) 0.274

    注:性别赋值,男=0,女=1;NAFLD赋值,否=0,是=1;糖尿病赋值,否=0,是=1。

    下载: 导出CSV

    表  4  老年非糖尿病患者骨质疏松组与非骨质疏松组一般资料

    Table  4.   Comparison of general information between osteoporosis group and non-osteoporosis group in the elderly without diabetes

    指标 骨质疏松组(n=261) 非骨质疏松组(n=233) 统计值 P
    女性[例(%)] 158(60.5) 76(32.6) χ2=38.487 <0.001
    年龄(岁) 78.02±8.55 75.53±9.54 t=5.736 0.003
    BMI(kg/m2 22.43±5.12 24.76±4.90 t=4.953 <0.001
    高血压病史[例(%)] 143(54.8) 145(62.2) χ2=2.805 0.094
    冠心病病史[例(%)] 59(22.6) 62(26.6) χ2=1.067 0.302
    颈动脉粥样硬化[例(%)] 207(79.3) 189(81.1) χ2=0.252 0.615
    NAFLD[例(%)] 83(31.8) 47(20.2) χ2=7.874 0.005
    下载: 导出CSV

    表  5  老年非糖尿病患者骨质疏松组与非骨质疏松组患者生化及代谢指标

    Table  5.   Comparison of biochemical and metabolic indicators between osteoporosis group and non-osteoporosis group in the elderly without diabetes

    指标 骨质疏松组(n=261) 非骨质疏松组(n=233) 统计值 P
    Hb(g/L) 125.59±18.49 131.99±15.13 t=0.891 <0.001
    FPG(mmol/L) 5.00±1.01 5.08±1.23 t=0.783 0.475
    ALT(U/L) 13(10~17) 16(13~22) Z=-0.413 0.679
    AST(U/L) 19(17~23) 20(17~24) Z=-0.019 0.984
    TC(mmol/L) 4.46±1.04 4.33±1.71 t=2.664 0.307
    TG(mmol/L) 1.20(0.88~1.58) 1.22(0.93~1.67) Z=-1.688 0.091
    LDL-C(mmol/L) 2.66±0.79 2.59±0.80 t=0.122 0.360
    Alb(g/L) 37.92±6.02 39.04±8.52 t=0.005 0.090
    UA(μmol/L) 320.15±86.67 355.91±84.96 t=0.105 <0.001
    TSH(uIU/mL) 1.77(1.16~2.90) 1.76(1.12~2.69) Z=-0.734 0.461
    FINS(μIU/mL) 6.67(4.50~10.08) 8.89(5.50~13.21) Z=-1.985 0.047
    HOMA-IR 1.39(0.89~2.24) 2.00(1.16~3.09) Z=-2.183 0.029
    25(OH)D(ng/mL) 31.31(23.45~43.12) 32.56(23.24~48.54) Z=-1.347 0.178
    BSAP(ng/mL) 11.09±6.32 8.78±3.56 t=16.030 <0.001
    TRAP(U/L) 4.23±2.26 3.59±1.15 t=12.000 <0.001
    下载: 导出CSV

    表  6  老年非糖尿病患者骨质疏松影响因素的Logistic回归分析结果

    Table  6.   Logistic regression analysis of influencing factors of osteoporosis in elderly patients without diabetes

    指标 回归系数 标准误 OR(95%CI P
    年龄 0.037 0.014 1.037(1.009~1.067) 0.010
    性别(女) 1.223 0.257 3.401(2.054~5.618) 0.000
    NAFLD 0.453 0.224 1.573(1.015~2.439) 0.043
    HOMA-IR -0.021 0.019 0.811(0.687~0.958) 0.014
    BMI -0.019 0.028 0.981(0.926~1.036) 0.489
    TSH 0.058 0.062 1.059(0.937~1.197) 0.356
    UA -0.001 0.002 0.999(0.996~1.002) 0.483
    Hb -0.003 0.001 0.997(0.978~1.016) 0.729

    注:性别赋值,男=0,女=1;NAFLD赋值,否=0,是=1。

    下载: 导出CSV
  • [1] SERIOLO B, PAOLINO S, CASABELLA A, et al. Osteoporosis in the elderly[J]. Aging Clin Exp Res, 2013, 25( Suppl 1): S27- S29. DOI: 10.1007/s40520-013-0107-9.
    [2] ABBASI M, FARZAM SA, MAMAGHANI Z, et al. Relationship between metabolic syndrome and its components with bone densitometry in postmenopausal women[J]. Diabetes Metab Syndr, 2017, 11( Suppl 1): S73- S76. DOI: 10.1016/j.dsx.2016.12.008.
    [3] SHANBHOGUE VV, FINKELSTEIN JS, BOUXSEIN ML, et al. Association between insulin resistance and bone structure in nondiabetic postmenopausal women[J]. J Clin Endocrinol Metab, 2016, 101( 8): 3114- 3122. DOI: 10.1210/jc.2016-1726.
    [4] National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology. Guidelines for management of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2010, 26( 2): 120- 124.

    中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南[J]. 临床肝胆病杂志, 2010, 26( 2): 120- 124.
    [5] JIN R, WANG XX, LIU F, et al. Research advances in pharmacotherapy for nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2022, 38( 7): 1634- 1640. DOI: 10.3969/j.issn.1001-5256.2022.07.033.

    靳睿, 王晓晓, 刘峰, 等. 非酒精性脂肪性肝病的药物治疗进展[J]. 临床肝胆病杂志, 2022, 38( 7): 1634- 1640. DOI: 10.3969/j.issn.1001-5256.2022.07.033.
    [6] PAN BJ, CAI J, ZHAO PP, et al. Relationship between prevalence and risk of osteoporosis or osteoporotic fracture with non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. Osteoporos Int, 2022, 33( 11): 2275- 2286. DOI: 10.1007/s00198-022-06459-y.
    [7] CUI R, SHENG H, RUI XF, et al. Low bone mineral density in Chinese adults with nonalcoholic fatty liver disease[J]. Int J Endocrinol, 2013, 2013: 396545. DOI: 10.1155/2013/396545.
    [8] MOON SS, LEE YS, KIM SW. Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women[J]. Endocrine, 2012, 42( 2): 423- 429. DOI: 10.1007/s12020-012-9639-6.
    [9] UPALA S, JARUVONGVANICH V, WIJARNPREECHA K, et al. Nonalcoholic fatty liver disease and osteoporosis: A systematic review and meta-analysis[J]. J Bone Miner Metab, 2017, 35( 6): 685- 693. DOI: 10.1007/s00774-016-0807-2.
    [10] MANTOVANI A, DAURIZ M, GATTI D, et al. Systematic review with meta-analysis: Non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density[J]. Aliment Pharmacol Ther, 2019, 49( 4): 375- 388. DOI: 10.1111/apt.15087.
    [11] KAYA M, IŞıK D, BEŞTAŞ R, et al. Increased bone mineral density in patients with non-alcoholic steatohepatitis[J]. World J Hepatol, 2013, 5( 11): 627- 634. DOI: 10.4254/wjh.v5.i11.627.
    [12] VACHLIOTIS ID, ANASTASILAKIS AD, GOULAS A, et al. Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications[J]. Diabetes Obes Metab, 2022, 24( 9): 1702- 1720. DOI: 10.1111/dom.14774.
    [13] MARCUCCI G, DOMAZETOVIC V, NEDIANI C, et al. Oxidative stress and natural antioxidants in osteoporosis: Novel preventive and therapeutic approaches[J]. Antioxidants(Basel), 2023, 12( 2): 373. DOI: 10.3390/antiox12020373.
    [14] SHI Y, LIU XY, JIANG YP, et al. Monotropein attenuates oxidative stress via Akt/mTOR-mediated autophagy in osteoblast cells[J]. Biomed Pharmacother, 2020, 121: 109566. DOI: 10.1016/j.biopha.2019.109566.
    [15] SUN S, XU MH, ZHUANG PJ, et al. Effect and mechanism of vitamin D activation disorder on liver fibrosis in biliary atresia[J]. Sci Rep, 2021, 11: 19883. DOI: 10.1038/s41598-021-99158-3.
    [16] DRAPKINA OM, ELKINA AY, SHEPTULINA AF, et al. Non-alcoholic fatty liver disease and bone tissue metabolism: Current findings and future perspectives[J]. Int J Mol Sci, 2023, 24( 9): 8445. DOI: 10.3390/ijms24098445.
    [17] LIU W, YUAN J, SU ZY, et al. Relationship between bone metabolism and insulin resistance in male type 2 diabetes mellitus patients from community with different body mass indexes[J]. J Clin Intern Med, 2018, 35( 3): 173- 176. DOI: 10.3969/j.issn.1001-9057.2018.03.009.

    刘薇, 原晶, 苏志燕, 等. 不同体重指数的社区男性2型糖尿病患者骨代谢与胰岛素抵抗的相关性研究[J]. 临床内科杂志, 2018, 35( 3): 173- 176. DOI: 10.3969/j.issn.1001-9057.2018.03.009.
    [18] ZENG R, HUANG SY, LIAO SB. Study on the influential factors of lumbar osteoporosis in postmenopausal women with type 2 diabetes mellitus[J]. Chin J Osteoporos, 2021, 27( 11): 1620- 1625. DOI: 10.3969/j.issn.1006-7108.2021.11.012.

    曾荣, 黄淑玉, 廖世波. 绝经后女性2型糖尿病患者腰椎骨质疏松的影响因素研究[J]. 中国骨质疏松杂志, 2021, 27( 11): 1620- 1625. DOI: 10.3969/j.issn.1006-7108.2021.11.012.
    [19] GAO M, LI SL. The research progress in the relationship between serum uric acid and osteoporosis[J]. Chin J Osteoporos, 2016, 22( 5): 641- 646. DOI: 10.3969/j.issn.1006-7108.2016.05.026.

    高萌, 李社莉. 血尿酸与骨质疏松症关系的研究进展[J]. 中国骨质疏松杂志, 2016, 22( 5): 641- 646. DOI: 10.3969/j.issn.1006-7108.2016.05.026.
    [20] ZHAO N, LI SM, FANG XX, et al. Study of the relationship between bone mineral density and serum uric acid in senile diabetic patients[J]. Chin J Osteoporos, 2014, 20( 7): 784- 788. DOI: 10.3969/j.issn.1006-7108.2014.07.013.

    赵娜, 李素梅, 方星星, 等. 老年糖尿病患者骨密度与血尿酸水平的相关研究[J]. 中国骨质疏松杂志, 2014, 20( 7): 784- 788. DOI: 10.3969/j.issn.1006-7108.2014.07.013.
    [21] ESTEP M, ABAWI M, JARRAR M, et al. Association of obestatin, ghrelin, and inflammatory cytokines in obese patients with non-alcoholic fatty liver disease[J]. Obes Surg, 2011, 21( 11): 1750- 1757. DOI: 10.1007/s11695-011-0475-1.
    [22] YAN DD, WANG J, HOU XH, et al. Association of serum uric acid levels with osteoporosis and bone turnover markers in a Chinese population[J]. Acta Pharmacol Sin, 2018, 39( 4): 626- 632. DOI: 10.1038/aps.2017.165.
    [23] HAN W, BAI XJ, WANG N, et al. Association between lumbar bone mineral density and serum uric acid in postmenopausal women: A cross-sectional study of healthy Chinese population[J]. Arch Osteoporos, 2017, 12( 1): 50. DOI: 10.1007/s11657-017-0345-0.
    [24] ZHANG BW, LEI T. Obesity and osteoporosis[J]. Int J Endocrinol Metab, 2010, 30( 4): 242- 244. DOI: 10.3760/cma.j.issn.1673-4157.2010.04.008.

    张宝伟, 雷涛. 肥胖与骨质疏松[J]. 国际内分泌代谢杂志, 2010, 30( 4): 242- 244. DOI: 10.3760/cma.j.issn.1673-4157.2010.04.008.
    [25] ASPRAY TJ, HILL TR. Osteoporosis and the ageing skeleton[J]. Subcell Biochem, 2019, 91: 453- 476. DOI: 10.1007/978-981-13-3681-2_16.
    [26] FENG C, XU ZW, TANG XJ, et al. Estrogen-related receptor α: A significant regulator and promising target in bone homeostasis and bone metastasis[J]. Molecules, 2022, 27( 13): 3976. DOI: 10.3390/molecules27133976.
    [27] MA YZ, WANG YP, LIU Q, et al. 2018 China guideline for the diagnosis and treatment of senile osteoporosis[J]. Chin J Gerontol, 2019, 39( 11): 2557- 2575. DOI: 10.3969/j.issn.1005-9202.2019.11.001.

    马远征, 王以朋, 刘强, 等. 中国老年骨质疏松诊疗指南(2018)[J]. 中国老年学杂志, 2019, 39( 11): 2557- 2575. DOI: 10.3969/j.issn.1005-9202.2019.11.001.
  • 加载中
表(6)
计量
  • 文章访问数:  209
  • HTML全文浏览量:  78
  • PDF下载量:  33
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-11-23
  • 录用日期:  2024-01-23
  • 出版日期:  2024-08-25
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回